NASDAQ: ADILAdial Pharmaceuticals Inc Stock
$0.35-0.03 (-7.89%)
Updated Mar 24, 2023
ADIL Price
$0.35
Fair Value Price
$0.58
Market Cap
$9.45M
52 Week Low
$0.20
52 Week High
$2.27
P/E
-0.51x
P/B
1.75x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$15.70M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.43
Operating Cash Flow
-$12M
Beta
0.66
Next Earnings
May 15, 2023
Ex-Dividend
N/A
Next Dividend
N/A
ADIL Overview
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ADIL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ADIL ($0.35) is undervalued by 38.87% relative to our estimate of its Fair Value price of $0.58 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ADIL ($0.35) is significantly undervalued by 38.87% relative to our estimate of its Fair Value price of $0.58 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ADIL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ADIL due diligence checks available for Premium users.
Be the first to know about important ADIL news, forecast changes, insider trades & much more!
ADIL News
Valuation
ADIL fair value
Fair Value of ADIL stock based on Discounted Cash Flow (DCF)
Price
$0.35
Fair Value
$0.58
Undervalued by
39.22%
ADIL ($0.35) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ADIL ($0.35) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ADIL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ADIL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.51x
Industry
17.88x
Market
21.37x
ADIL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.75x
Industry
4.89x
ADIL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ADIL's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.1M
Profit Margin
0%
ADIL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$7.7M
Liabilities
$2.3M
Debt to equity
0.43
ADIL's short-term assets ($6.77M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ADIL's short-term assets ($6.77M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ADIL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.4M
Investing
$0.0
Financing
$0.0
ADIL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ADIL vs Biotech Stocks
Adial Pharmaceuticals Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.